Showing results (821-830 of 6,303) with videos related to
Sort By:
Pageof 631
Diabetes, Obesity & Metabolism|May 31, 2022
Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trialTaha Sen, Akihiko Koshino, Bruce Neal, et al.Diabetes, Obesity & Metabolism|May 31, 2022
Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney diseaseBenjamin P Larkin, Long T Nguyen, Miao Hou, et al.Diabetes, Obesity & Metabolism|June 4, 2021
Development of application to automatically calculate mean amplitude of glycaemic excursions using intermittently scanned continuous glucose monitoring dataAya Kitae, Tetsuya Kimura, Chihiro Munekawa, et al.Diabetes, Obesity & Metabolism|July 2, 2021
High-fat diet prevents the development of autoimmune diabetes in NOD miceAmy L Clark, Zihan Yan, Sophia X Chen, et al.Diabetes, Obesity & Metabolism|June 28, 2021
A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludecViral N Shah, Halis K Akturk, Hal Joseph, et al.Diabetes, Obesity & Metabolism|June 9, 2021
Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?Akinobu Nakamura, Kazuno Omori, Yasuo TerauchiDiabetes, Obesity & Metabolism|June 9, 2021
Weight-reducing, lipid-lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high-fat-fed miceShruti Mohan, Peter R Flatt, Nigel Irwin, et al.Diabetes, Obesity & Metabolism|June 14, 2021
Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trialXiang Yan, Shan Jiang, Ying Lou, et al.Diabetes, Obesity & Metabolism|March 17, 2020
Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetesKun-Ho Yoon, Jahoon Kang, Se Chang Kwon, et al.Diabetes, Obesity & Metabolism|February 4, 2020
Metformin and cardiorenal outcomes in diabetes: A reappraisalJohn R Petrie, Peter R Rossing, Ian W CampbellPageof 631